Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Public ClinicalTrials.gov record NCT01586195. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Study identification
- NCT ID
- NCT01586195
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Interventions
- Vemurafenib Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2011
- Primary completion
- Apr 29, 2015
- Completion
- Apr 29, 2015
- Last update posted
- May 24, 2017
2011 – 2015
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| UCSD Moores Cancer Center | La Jolla | California | 92093 | — |
| UCLA School of Medicine; Hematology/Oncology | Los Angeles | California | 90095 | — |
| The Angeles Clinic and Research Institute, Santa Monica Office | Santa Monica | California | 90025 | — |
| University of Colorado; Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University; Winship Cancer Institute | Atlanta | Georgia | 30308 | — |
| Oncology Specialists, S.C. | Park Ridge | Illinois | 60068 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Mid Ohio Onc Hematology Inc | Columbus | Ohio | 43219 | — |
| UPCI Cancer Institute; Cancer Pavillion | Pittsburgh | Pennsylvania | 15232 | — |
| Vanderbilt Univ Medical Ctr | Nashville | Tennessee | 37232 | — |
| Texas Oncology-Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01586195, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 24, 2017 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01586195 live on ClinicalTrials.gov.